Breast Cancer Coverage from Every Angle

Elizabeth A. Mittendorf, MD, PhD, on Breast Cancer Immunotherapy: Expert Perspective

Posted: Tuesday, March 5, 2019

Elizabeth A. Mittendorf, MD, PhD, of Dana-Farber Cancer Institute, discusses what makes the combination of immune checkpoint inhibitors and PARP inhibitors so appealing in the treatment of BRCA-mutation carriers.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.